🔹 Adj EPS $1.72 (Est $1.63)🟢
🔹 Revenue: $15.62B (Est. $15.49B) 🟢; UP +7% YoY
🔹 Pharmaceutical: $14.04B (Est. $14.00B) 😐; UP +7% YoY
🔹 Animal Health: $1.40B (Est. $1.34B) 🟢; UP +9% YoY
FY25 Guidance
🔹 Revenue: $64.1B-$65.6B (Est. $67.3B) 🔴
🔹 EPS: $8.88-$9.03 (Est. $9.21) 🔴
Key Product Performance
🔹 KEYTRUDA Sales: $7.84B; UP +19% YoY
🔹 GARDASIL/GARDASIL 9 Sales: $1.55B; DOWN -17% YoY
🔹 JANUVIA/JANUMET Sales: $487M; DOWN -38% YoY
🔹 WINREVAIR Sales: $200M (New launch)
Strategic Updates & Pipeline Developments
🔸 Positive Phase 3 Results for Subcutaneous Pembrolizumab With Berahyaluronidase Alfa
🔸 FDA Acceptance of Biologics License Application for Clesrovimab (RSV prevention in infants)
🔸 Global Licenses Secured for MK-2010 (Anti-PD-1/VEGF Bispecific) & MK-4082 (Oral GLP-1 Agonist)
🔸 Approval of GARDASIL for Males in China (January 2025)
CEO Robert M. Davis' Commentary
🔸 "We delivered strong growth in 2024, driven by demand for our innovative portfolio, particularly KEYTRUDA, WINREVAIR, and Animal Health. Our continued pipeline advancement and strategic licensing deals reinforce our confidence in long-term growth."